Alligator Bioscience
Scheelevägen 19 A
Lund
223 70
Tel: 46-0-46-286-4280
Fax: 46-0-46-286-4290
Website: http://www.alligatorbioscience.com/
Email: info@alligatorbioscience.com
122 articles about Alligator Bioscience
-
Alligator Bioscience: ADC-1013 Clinical Phase I Data to be Presented at ASCO
5/16/2019
Alligator Bioscience, announces that Janssen Biotech, Inc. will present data from a Phase I clinical study of ADC-1013 at the upcoming ASCO Annual meeting held in Chicago on May 31- June 4.
-
The Nomination Committee's Proposal for the Annual Shareholders' Meeting in Alligator Bioscience AB (publ)
4/17/2019
Alligator Bioscience, announces that the Nomination Committee in Alligator Bioscience has presented its proposal for the annual shareholders' meeting on May 9, 2019, regarding election and remuneration of the board.
-
Alligator Bioscience to Present New Preclinical Data on ATOR-1015 at PEGS Boston
4/10/2019
Tumor-localizing properties of bispecific antibody demonstrated by live imaging
-
Notice of Annual Shareholders' Meeting in Alligator Bioscience AB (publ)
4/10/2019
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
-
Alligator Bioscience: New Preclinical Data for ATOR-1144 Demonstrate Potential for Activation of Both the Innate and the Adaptive Immune System, as well as Direct Anti-tumor Effects
4/2/2019
Alligator Bioscience, announce that new preclinical data on the drug candidate ATOR-1144 will be presented at the scientific conference AACR, held in Atlanta on March 29 - April 3, 2019.
-
Alligator Bioscience's Annual Report 2018 Published
3/22/2019
Alligator Bioscience announced that the Annual Report 2018 is available at the company website www.alligatorbioscience.com.
-
Alligator Bioscience: New Preclinical Data Demonstrate Strong Anti-tumor Effects for the 4-1BB Antibody ATOR-1017
3/18/2019
ATOR-1017 is a monoclonal antibody in development for the treatment of metastasizing cancer.
-
Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015
3/7/2019
Dose-escalation study commences with first-in-class bispecific CTLA-4 antibody
-
Alligator Bioscience AB Year-end Report 2018
2/14/2019
The bispecific drug candidate ATOR-1015 in clinical development
-
Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update
2/12/2019
Alligator Bioscience - On 14 February 2019, at 08:00 a.m. CET, Alligator Bioscience will publish its report for the year ended 31 December 2018.
-
Alligator Bioscience Publishes Clinical Phase I Data for ADC-1013 in the International Journal of Cancer
1/29/2019
First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
-
Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015
12/11/2018
A first-in-class bispecific CTLA-4 antibody
-
Alligator Bioscience to Receive Million-dollar Payments - AbClon Partner Exercises Option
11/7/2018
Alligator Bioscience today announces that it will receive payments of more than USD 3.5 million under its collaboration agreement with the South Korean company AbClon Inc.
-
Alligator Bioscience Expands Pipeline: Preclinical Development Initiated for the Candidate Drug ATOR-1144
10/30/2018
New candidate drug selected - the bispecific tumor-localizing CTLA-4 x GITR antibody ATOR-1144
-
Alligator Bioscience AB Interim Report January-September 2018
10/26/2018
The science behind the Nobel Prizes in Medicine and Chemistry constitutes the core in Alligator's research and development.
-
Alligator Bioscience Receives Government Research Grant
10/5/2018
Alligator Bioscience AB today announced that they will receive a 500 000 SEK grant from Sweden's government agency for innovation, Vinnova, for the project 'Verification of the unique functionality of ATOR-1017 by 3D structure determination'.
-
Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
7/19/2018
Alligator Bioscience announced that the company has submitted a clinical trial authorization (CTA) application to the relevant regulatory authorities to start a phase I study of its wholly-owned bispecific drug candidate ATOR-1015.
-
Alligator Bioscience AB Interim Report January-June 2018
7/12/2018
Positive data for our preclinical projects
-
Alligator Bioscience's ATOR-1017 Strongly Activates Both T cells and NK Cells, Important for the Effective Eradication of Tumor Cells
6/21/2018
Further preclinical findings support a best-in-class profile
-
Alligator Bioscience: ATOR-1017 Pre-clinical Data Support a Best-in-class 4-1BB Antibody Profile
5/3/2018
- Unique binding profile and cross-linking properties - Oral presentation at Protein Engineering Summit in Boston, US